ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer

Colombo, NicolettaColeman, Robert L.Wu, XiaohuaKose, FatihWenham, Robert MichaelSebastianelli, AlexandraHasegawa, KoseiZsiros, EmeseRouge, Thibault De la MotteBidzinski, MariuszMcNeish, Iain A.Sehouli, JalidKorach, JacobDebruyne, Philip R.Kim, Jae-WeonDe Melo, Andrea C.Peng, XuanBogusz, Agata M.Yamada, Karin SayuriMonk, Bradley J.2022-11-042022-11-0420220732-183Xhttp://hdl.handle.net/11727/8008enginfo:eu-repo/semantics/closedAccessENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancerConference Object4016000863680305016